Perrigo Company PLC (NYSE:PRGO) EVP Svend Andersen purchased 7,200 shares of Perrigo stock in a transaction dated Tuesday, August 14th. The shares were acquired at an average cost of $69.43 per share, for a total transaction of $499,896.00. The transaction was disclosed in a filing with the SEC, which is available through this link.

PRGO stock opened at $72.96 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.23 and a current ratio of 1.81. Perrigo Company PLC has a fifty-two week low of $67.53 and a fifty-two week high of $95.93. The company has a market cap of $9.56 billion, a P/E ratio of 14.80, a PEG ratio of 1.74 and a beta of 0.84.

Perrigo (NYSE:PRGO) last released its earnings results on Thursday, August 9th. The company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.21 by $0.01. Perrigo had a net margin of 4.77% and a return on equity of 11.92%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.23 billion. During the same period in the prior year, the firm earned $1.22 earnings per share. The business’s quarterly revenue was down 4.2% compared to the same quarter last year. analysts anticipate that Perrigo Company PLC will post 4.95 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 18th. Shareholders of record on Friday, August 31st will be paid a $0.19 dividend. The ex-dividend date of this dividend is Thursday, August 30th. This represents a $0.76 annualized dividend and a yield of 1.04%. Perrigo’s dividend payout ratio is currently 15.42%.

PRGO has been the topic of several research reports. Cantor Fitzgerald set a $107.00 price target on shares of Perrigo and gave the stock a “buy” rating in a research report on Tuesday, May 8th. Wells Fargo & Co cut their target price on shares of Perrigo from $90.00 to $84.00 and set a “market perform” rating on the stock in a research note on Monday, May 14th. Canaccord Genuity set a $105.00 target price on shares of Perrigo and gave the stock a “buy” rating in a research note on Monday, May 14th. Royal Bank of Canada cut their target price on shares of Perrigo from $89.00 to $67.00 and set a “hold” rating on the stock in a research note on Friday, August 10th. Finally, Deutsche Bank lowered shares of Perrigo from a “buy” rating to a “hold” rating and cut their target price for the stock from $93.00 to $78.00 in a research note on Friday, August 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $89.06.

A number of institutional investors have recently made changes to their positions in PRGO. Piedmont Investment Advisors LLC purchased a new position in Perrigo in the second quarter valued at approximately $110,000. Dupont Capital Management Corp increased its stake in Perrigo by 63.8% in the second quarter. Dupont Capital Management Corp now owns 1,705 shares of the company’s stock valued at $124,000 after purchasing an additional 664 shares during the last quarter. Twin Tree Management LP increased its stake in Perrigo by 271.0% in the first quarter. Twin Tree Management LP now owns 2,223 shares of the company’s stock valued at $185,000 after purchasing an additional 3,523 shares during the last quarter. Allianz Asset Management GmbH purchased a new position in Perrigo in the first quarter valued at approximately $205,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Perrigo in the first quarter valued at approximately $208,000. Institutional investors own 80.89% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.

See Also: Momentum Indicator: Relative Strength Index

Insider Buying and Selling by Quarter for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.